We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

HPV, p16 Offers Different Prognostic Clues in Oropharyngeal Cancer

By LabMedica International staff writers
Posted on 07 Oct 2020
Print article
Image: Photomicrograph of histology of a poorly differentiated squamous cell carcinoma (SCC) that is p16 positive (Photo courtesy of Nephron).
Image: Photomicrograph of histology of a poorly differentiated squamous cell carcinoma (SCC) that is p16 positive (Photo courtesy of Nephron).
Human papillomavirus infection (HPV infection) is an infection caused by human papillomavirus (HPV), a DNA virus from the Papillomaviridae family. About 90% of HPV infections cause no symptoms and resolve spontaneously within two years.

Human papillomavirus-positive oropharyngeal cancer (HPV-positive OPC or HPV+OPC), is a squamous cell carcinoma of the throat caused by the human papillomavirus type 16 virus. Detection of a tumor suppressor protein, known as p16, is commonly used to diagnose an HPV associated OPC.

Oncologists at the Catalan Institute of Oncology (Barcelona, Spain) retrospectively analyze clinical features and outcomes in relation to p16 and HPV status in more than 7,700 individuals with oropharyngeal cancer enrolled in 13 cohorts from sites in nine European or North American countries. HPV and p16 were measured by immunohistochemistry (IHC) and the HPV DNA in situ hybridization (ISH) assay, respectively which can identify clusters of oropharyngeal cancers that appear to be at intermediate risk of recurrence or death compared to tumors that are p16-positive and HPV-positive and those lacking both markers.

IHC profiling is a sensitive approach for picking up p16, a surrogated marker for HPV, albeit with reduced specificity, since that host protein sometimes has enhanced expression even in the absence of HPV infection. On the other hand, the DNA ISH test is less sensitive, since it depends to some extent on the viral load, though it is also far more specific for finding risky HPV strains. Based on analyses done at a centralized site, the team classified 416 cases as p16-positive and HPV-negative, while 279 individuals with oropharyngeal cancer had p16-negative tumors testing positive for HPV by DNA ISH. The remaining patients included 3,598 with p16-negative and HPV-negative tumors and 3,409 cases classified as positive for both markers.

Nearly 90% of the p16-negative, HPV-negative cancers occurred in smokers, compared to a smoking rate of 62% in the patients with p16-positive, HPV-positive tumors. Notably, the cases showing discordant p16 and HPV marker status had smoking history in between these two groups. The team also saw a range of treatment interventions, including an uptick in surgeries and palliative care in the p16- and HPV-negative cases, followed by cases with HPV but not p16. When the investigators looked at overall survival in the biomarker-defined groups of stage III or IVa/b, locally advanced oropharyngeal cancer cases, they found that significantly more patients with p16- and HPV-positive tumors were alive after five years, whereas outcomes were more dire for the p16- and HPV-negative cases.

Miren Taberna, MD, a clinical oncologist and senior author of the study, said, “Using p16 staining alone, 11% of oropharyngeal cancer patients would be incorrectly classified as HPV-related, suggesting incorrect prognostic conclusions could be drawn from p16 testing alone, which would potentially place these patients in a de-escalation group inappropriately.” The study was presented at the European Society for Medical Oncology's Virtual Congress held in September 2020.

Related Links:
Catalan Institute of Oncology

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.